Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for MGUS-Associated Neuropathy
NCT00665652Phase 2Terminated
- Sponsor
- Dartmouth Health
- Start
- Apr 2008
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in monoclonal gammopathy of undetermined significance (MGUS), peripheral neuropathy, sponsored by Dartmouth Health. Started Apr 2008; status: terminated.
02
Drugs
lenalidomide
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)peripheral neuropathy
Beyond the preview
Go deeper on NCT00665652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665652.